SGO Annual Meeting | Conference

Researchers Seek to Optimize PARP Inhibitors in Ovarian Cancer

March 21st 2016

Shannon Westin, MD, discusses refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities.

New Antiemetic Compares Favorably With Standard for Cisplatin Regimens

March 21st 2016

An investigational extended-release formulation of the antiemetic granisetron achieved a complete response more often than did ondansetron in cancer patients receiving highly emetogenic cisplatin-based chemotherapy.

Dr. Terri Febbraro on the Inverse Correlation Between Time on Chemotherapy and OS

March 21st 2016

Terri Febbraro, MD, third year fellow, University of Chicago/NorthShore University Health System, discusses length of time receiving chemotherapy versus overall survival in patients with ovarian cancer. Febbraro says the study looked at three separate groups of patients with ovarian cancer based on the length of time they receieved chemotherapy, with the group being on chemotherapy the longest having the worst overall survival rates.

Dr. Martee Hensley on Trabectedin as a Treatment for Uterine Leiomyosarcoma

March 21st 2016

Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.

Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma

March 20th 2016

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Dr. Emily Ko on the Role of Surgery in Endometrial Cancer

March 20th 2016

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses the role of surgery in endometrial cancer and the candidacy of patients for the procedure.

Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer

March 20th 2016

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

Dr. Terri Woodard on Preservative Measures for Women With Ovarian Cancer

March 20th 2016

Terri Woodard, MD, assistant professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses if conservative management for women with ovarian cancer is warranted.

BRCA Mutations Linked to Longer Survival in Ovarian Cancer

March 19th 2016

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival outcomes versus patients without HR mutations.

Dr. Markman on the Future of Treatment for Ovarian Cancer

April 13th 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

Dr. Secord on Understanding Patient Preferences

April 10th 2015

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the importance of understanding patient preferences regarding treatment regimens.

Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer

April 7th 2015

Ursula A. Matulonis, MD, medical director, gynecologic oncology, Susan F. Smith Center for Women's Cancers, institute physician, Dana-Farber Cancer Institute, discusses managing toxicities associated with olaparib for patients with ovarian cancer.

Fosbretabulin/Bevacizumab Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

March 31st 2015

Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.

Bevacizumab Regimen Shows Survival Trend in Phase III Ovarian Cancer Trial

March 30th 2015

Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Studies Illuminate Olaparib's Continued Role in Ovarian Cancer

March 30th 2015

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib in the treatment of women with ovarian cancer, according to Ursula A. Matulonis, MD.